Minzasolmin clinical trials
Also written UCB0599.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses minzasolmin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- UCB0599
- 3
Studies by the year they started
4 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses minzasolmin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's DiseaseTerminatedPhase 2UCB Biopharma SRLNCT05543252Written as Minzasolmin (UCB0599)How we know
- A Study to Assess the Bioavailability of a New Tablet Formulation of Minzasolmin and the Effect of Food in Healthy ParticipantsCompletedPhase 1UCB Biopharma SRLNCT06533475Written as Minzasolmin tablet formulation under fasting conditionHow we know
- A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's DiseaseCompletedPhase 2UCB Biopharma SRLNCT04658186Written as UCB0599How we know
- A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)CompletedPhase 1UCB Biopharma S.P.R.L.NCT04875962Written as UCB0599How we know
Given beside what is tested · 1 — minzasolmin is usual care or a partner of the new treatment
Codes
What other systems call minzasolmin · ClinicalTrials.gg INT014698
- UNII (FDA) 3N0435TG2DMINZASOLMINOne source FDA
- NCI Thesaurus C188507MinzasolminOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3N0435TG2D | MINZASOLMIN | One source FDA |
| NCI Thesaurus | C188507 | Minzasolmin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.